1. Kimball SR, Vary TC, Jefferson LS. Regulation of protein synthesis by
insulin. Annu Rev Physiol. 1994;56:321-48.
2. Randazzo PA, Morey VA, Polishook AK, Jarett L. Characterization of the
growth of murine fibroblasts that express human insulin receptors. I. The
effect of insulin in the absence of other growth factors. Exp Cell Res.
1990;190(1):25-30.
3. Taub R, Roy A, Dieter R, Koontz J. Insulin as a growth factor in rat
hepatoma cells. Stimulation of proto-oncogene expression. J Biol Chem.
1987;262(22):10893-7.
4. Sell SM, Reese D, Ossowski VM. Insulin-inducible changes in insulin
receptor mRNA splice variants. J Biol Chem. 1994;269(49):30769-72.
5. Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin
Endocrinol Metab. 2006;20(4):665-79.
6. White MF. The insulin signalling system and the IRS proteins.
Diabetologia. 1997;40(Suppl 2):S2-17.
7. Avruch J. Insulin signal transduction through protein kinase cascades.
Mol Cell Biochem. 1998;182(1-2):31-48.
8. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL.
Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and
sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell.
2000;6(1):77-86.
9. Hoeffer CA, Klann E. mTOR signaling : at the crossroads of plasticity,
memory and diseases. Trends Neurosci. 2010;33(2):67-75.
10. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for
insulin resistance. Sci STKE. 2005;2005(268):pe4.
11. Thirone AC, Huang C, Klip A. Tissue-specific roles of IRS proteins in
insulin signaling and glucose transport. Trends Endocrinol Metab.
2006;17(2):72-8.
12. Previs SF, Withers DJ, Ren JM, White MF, Shulman GI. Contrasting effects
of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism
in vivo. J Biol Chem. 2000;275(50):38990-4.
13. Ide T, Shimano H, Yahagi N, et al. SREBPs suppress IRS-2-mediated
insulin signalling in the liver. Nat Cell Biol. 2004;6(4):351-7.
14. Taniguchi CM, Ueki K, Kahn R. Complementary roles of IRS-1 and IRS-2 in
the hepatic regulation of metabolism. J Clin Invest. 2005;115(3):718-27.
15. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link
between hepatitis C virus infection and diabetes mellitus in a cirrhotic
population. J Hepatol. 1994;21(6):1135-9.
16. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and
chronic hepatitis C virus infection. Hepatology. 1999;29(2):328-33.
17. Antonelli A, Ferri C, Fallahi P, et al. Hepatitis C virus infection:
evidence for an association with type 2 diabetes. Diabetes Care.
2005;28(10):2548-50.
18. Lecube A, Hernбndez C, Genescа J, et al. Diabetes is the main factor
accounting for the high ferritin levels detected in chronic hepatitis C
virus infection. Diabetes Care. 2004;27(11):2669-75.
19. Negro F. Insulin resistance and HCV: will new knowledge modify clinical
management? J Hepatol. 2006;45(4):514-9.
20. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in
chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA
level, and liver fibrosis. Gastroenterology. 2008;134(2):416-23.
21. Romero-Gуmez M. Insulin resistance and hepatitis C. World J
Gastroenterol. 2006;12(44):7075-80.
22. Banerjee S, Saito K, Ait-Goughoulte M, et al. Hepatitis C virus core
protein upregulates serine phosphorylation of insulin receptor substrate-1
and impairs the downstream akt/protein kinase B signaling pathway for
insulin resistance. J Virol. 2008;82(6):2606-12.
23. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid
abnormalities: clinical and pathogenic data. Liver Int. 2009; Suppl 2:26-37.
24. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis
C viral infection. J Gastroenterol. 2009;44(Suppl 19):82-8.
25. Del Campo JA, Romero-Gуmez M. Steatosis and insulin resistance in
hepatitis C: a way out for the virus? World J Gastroenterol.
2009;15(40):5014-9.
26. Miquilena-Colina ME, Cabello EL, Saґnchez-Campos S, et al. Hepatic fatty
acid translocase CD36 upregulation is associated with insulin resistance,
hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis
and chronic hepatitis C. Gut. 2011;doi:10.1136.
27. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows
a cytoplasmic localization and associates to cellular lipid storage
droplets. Proc Natl Acad Sci U S A. 1997;94(4):1200-5.
28. Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the
peroxisome proliferator-activated receptor alpha during hepatitis C virus
infection. Gastroenterology. 2005;128(2):334-42.
29. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in
fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell.
1994;79(7):1147-56.
30. Kim KH, Hong SP, Kim K, et al. HCV core protein induces hepatic lipid
accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun.
2007;355(4): 883-8.
31. Abid K, Pazienza V, de Gottardi A, et al. An in vitro model of hepatitis
C virus genotype 3a-associated triglycerides accumulation. J Hepatol.
2005;42(5):744-51.
32. Fukasawa M, Tanaka Y, Sato S, et al. Enhancement of de novo fatty acid
biosynthesis in hepatic cell line Huh7 expressing hepatitis C virus core
protein. Biol Pharm Bull. 2006;29(9):1958-61.
33. Pazienza V, Clйment S, Pugnale P, et al. Gene expression profile of
Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins.
Liver Int. 2009;29(5):661-9.
34. Narita R, Abe S, Kihara Y, et al. Insulin resistance and insulin
secretion in chronic hepatitis C virus infection. J Hepatol.
2004;41(1):132-8.
35. Lecube A, Hernбndez C, Genescа J, Simу R. Glucose abnormalities in
patients with hepatitis C virus infection: Epidemiology and pathogenesis.
Diabetes Care. 2006;29(5):1140-9.
36. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of
diabetes: a systematic review and meta-analysis. J Hepatol.
2008;49(5):831-44.
37. Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection.
Cell Death Differ. 2003;10(Suppl 1):S48-58.
38. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis
to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99-S112.
39. Seki S, Kitada T, Yamada T, et al. In situ detection of lipid
peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases.
J Hepatol. 2002;37(1):56-62.
40. Nedvнdkovб J, Smitka K, Kopskэ V, Hainer V. Adiponectin, an
adipocyte-derived protein. Physiol Res. 2005;54(2):133-40.
41. You T, Yang R, Lyles MF, et al. Abdominal adipose tissue cytokine gene
expression: relationship to obesity and metabolic risk factors. Am J Physiol
Endocrinol Metab. 2005;288(4):E741-7.
42. Nkontchou1G, Bastard JP, Ziol M, et al. Insulin resistance, serum
leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis.
J Hepatol. 2010;53:827–833.
43. Clйment S, Pascarella S, Negro F. Hepatitis C Virus Infection: Molecular
Pathways to Steatosis, Insulin Resistance and Oxidative Stress. Viruses.
2009;1:126-143.
44. Fujita N, Sugimoto R, Ma N, et al. Comparison of hepatic oxidative DNA
damage in patients with chronic hepatitis B and C. J Viral Hepat.
2008;15(7):498-507.
45. Romero MJ, Bosch-Morell F, Romero B, et al. Serum malndialdehyde :
possible use for the clinical management of chronic hepatitis C patients.
Free Radic Biol Med. 1998;25:993-97.
46. Mitsuyoshi H, Itoh Y, Sumida Y, et al. Evidence of oxidative stress as a
cofactor in the development of insulin resistance in patients with chronic
hepatitis C. Hepatol Res. 2008;38(4):348-53.
47. Vendemiale G, Grattagliano I, Portincasa P, et al. Oxidative stress in
symptom-free HCV carriers: relation with ALT flare-up. Eur J Clin Invest.
2001;31(1):54-63.
48. Joyce MA, Walters KA, Lamb SE, et al. HCV induces oxidative and ER
stress and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS
Pathog. 2009;5:e1000291.
49. Romero-Gуmez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance
impairs sustained response rate to peginterferon plus ribavirin in chronic
hepatitis C patients. Gastroenterology. 2005;128(3):636-41.
50. Harrison SA. Correlation between insulin resistance and hepatitis C
viral load. Hepatology. 2006;43(5):1168.
51. Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated
with insulin resistance in patients with chronic hepatitis C. Liver Int.
2008;28(2):271-7.
52. Mohammed Eslam, Mahmoud Aboelneen Khattab, Stephen A Harrison. Insulin
resistance and hepatitis C: an evolving story. Gut. 2011; DOI: 10.1136.
53. Ishida H, Li K, Yi M, Lemon SM. p21-activated kinase 1 is activated
through the mammalian target of rapamycin/p70 S6 kinase pathway and
regulates the replication of hepatitis C virus in human hepatoma cells. J
Biol Chem. 2007;282(16):11836-48.
54. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of
insulin resistance, steatosis, and fibrosis in chronic hepatitis C.
Hepatology. 2008;48(3):723-31.
55. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3
chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin
resistance and hepatic steatosis. Hepatology. 2006;44(6):1648-55.
56. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis,
inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of
individual patient data. Gastroenterology. 2006;130(6):1636-42.
57. Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes
mellitus and early insulin resistance in chronic hepatitis C. J Hepatol.
2001;35(2):279-83.
58. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular
carcinoma: A cohort study in high prevalence area of hepatitis virus
infection. Hepatology. 2006;43(6):1295-302.
59. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a
metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987-1000.
60. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa
B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J
Obes Relat Metab Disord. 2003;27(Suppl 3):S49-52.
61. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to
obesity-induced insulin resistance. Nat Med. 2005;11(2):191-8.
62. Gao Z, Hwang D, Bataille F, et al. Serine phosphorylation of insulin
receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem.
2002;277(50):48115-21.
63. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in
hepatitis C is not associated with virus-specific changes in adipocytokines.
Hepatology. 2007;46(1):66-73.
64. Knobler H, Zhornicky T, Sandler A, et al. Tumor necrosis
factor-alpha-induced insulin resistance may mediate the hepatitis C
virus-diabetes association. Am J Gastroenterol. 2003;98(12):2751-6.
65. Crespo J, Rivero M, Fбbrega E, et al. Plasma leptin and TNF-alpha levels
in chronic hepatitis C patients and their relationship to hepatic fibrosis.
Dig Dis Sci. 2002;47(7):1604-10.
66. Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor
receptors in chronic hepatitis C: a correlation with histological fibrosis
and activity. J Hepatol. 1999;30(2):185-91.
67. Aytug S, Reich D, Sapiro LE, et al. Impaired IRS-1/PI3-kinase signaling
in patients with HCV: a mechanism for increased prevalence of type 2
diabetes. Hepatology. 2003;38(6):1384-92.
68. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus
down-regulates insulin receptor substrates 1 and 2 through up-regulation of
suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499-508.
69. Miyamoto H, Moriishi K, Moriya K, et al. Involvement of the
PA28gamma-dependent pathway in insulin resistance induced by hepatitis C
virus core protein. J Virol. 2007;81(4):1727-35.
70. Conjeevaram HS, Wahed AS, Afdhal N, et al. Changes in Insulin
Sensitivity and Body Weight During and After Peginterferon and Ribavirin
Therapy for Hepatitis C. Gastroenterology. 2011;140:469–477.
71. Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signaling
3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis:
Insulin resistance and response to antiviral therapy. Hepatology.
2007;46(4):1009-15.
72. Persico M, Capasso M, Russo R, et al. Elevated expression and
polymorphisms of SOCS3 influence patient response to antiviral therapy in
chronic hepatitis C. Gut. 2008;57(4):507-15.
73. Georgopoulou U, Tsitoura P, Kalamvoki M, Mavromara P. The protein
phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A
protein. Biochimie. 2006;88(6):651-62.
74. Bernsmeier C, Duong FH, Christen V, et al. Virus-induced over-expression
of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis
C. J Hepatol. 2008;49(3):429-40.
75. Duong FH, Filipowicz M, Tripodi M, et al. Hepatitis C virus inhibits
interferon signaling through up-regulation of protein phosphatase 2A.
Gastroenterology. 2004;126(1):263-77.
76. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by
lipid-activated nuclear receptors. Nature. 2008;454(7203):470-7.
77. Tanaka N, Moriya K, Kiyosawa K, et al. PPARalpha activation is essential
for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma
in mice. J Clin Invest. 2008;118(2):683-94.
78. Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic
gluconeogenesis through AMP-activated protein kinase-dependent regulation of
the orphan nuclear receptor SHP. Diabetes. 2008;57(2):306-14.
79. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. Metformin rapidly
increases insulin receptor activation in human liver and signals
preferentially through insulin-receptor substrate-2. J Clin Endocrinol
Metab. 2003;88(3):1323-32.
80. Serfaty L, Fartoux L, Poupon R. Pioglitazone as adjuvant therapy in
chronic hepatitis C: sequential rather than concomitant administration with
pegylated interferon and ribavirin? J Hepatol. 2009;50(6):1269-71.
81. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits
mitochondrial electron transport and increases reactive oxygen species (ROS)
production. J Biol Chem. 2005;280(45):37481-8.
82. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin
Gastroenterol. 2006;40(Suppl 1):S17-29.
83. Moucari R, Forestier N, Larrey D, et al. Danoprevir, an HCV NS3/4A
protease inhibitor, improves insulin sensitivity in patients with genotype 1
chronic hepatitis C. Gut. 2010;59:1694-1698.
84. Petrides AS, Stanley T, Matthews DE, et al.Insulin resistance in
cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin
sensitivity. Hepatology. 1998;28(1):141-9.
85. Gabbay E, Zigmond E, Pappo O, et al. Antioxidant therapy for chronic
hepatitis C after failure of interferon: results of phase II randomized,
double-blind placebo controlled clinical trial. World J Gastroenterol.
2007;13(40):5317-23.
86. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance
and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45(1):80-7.
87. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral
therapy is associated with obesity and increased hepatic expression of
suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic
hepatitis C, viral genotype 1. Gut. 2006;55(4):529-35.